Novavax Announces Closing of Public Offering
The company issued 34,848,507 shares of its common stock, including 4,545,457 shares pursuant to the underwriters’ option to purchase additional shares. The shares were issued at
Net proceeds from the offering are to be used for general corporate purposes, including but not limited to working capital, capital expenditures, research and development expenditures related to clinical and preclinical vaccine candidates, clinical trial expenditures, as well as acquisitions and other strategic purposes.
The shares described above were issued pursuant to a final prospectus supplement and accompanying prospectus. The company filed the final prospectus supplement relating to the offering with the
Statements contained in this release using words such as "expects" and "intends" are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to: the possible adverse impact on the market price of our shares of common stock due to the dilutive effect of the securities sold in the offering; our planned use of the proceeds from this offering; capital market risks; our ability to raise additional capital when needed; and other risk factors identified from time to time in the reports we file with the
Senior Manager, Investor & Public Relations
Source: Novavax, Inc.